How to Read a Peptide Certificate of Analysis

A Certificate of Analysis is the single most important document attached to any peptide lot. It is the only artifact that ties a specific physical vial to a specific set of laboratory test results, and it is what a clinician, researcher, or procurement officer is actually asking to see when they request "documentation."

A well-constructed COA should answer four questions without ambiguity: what is in the vial, how much of it is in the vial, how clean it is, and whether it is safe to handle in the intended research context. This article walks through each section a practitioner should expect to find and what acceptable specifications look like.

The top of any COA should identify the compound by name and any synonyms or research codes; the lot number; the manufacturing date; the retest or expiry date; the storage condition under which the data was generated; and the issuing laboratory and quality officer with signature.

A COA without a signed quality officer or without a traceable lot number is not a COA — it is a marketing sheet. Both elements should be present before any further evaluation.

Identity is established by measuring the molecular mass of the peptide and comparing it to the theoretical mass of the intended sequence. The standard method is electrospray ionization mass spectrometry (ESI-MS), with high-resolution time-of-flight or Orbitrap analyzers preferred for higher mass accuracy.

The COA should show the observed mass, the theoretical mass, and the deviation in daltons or parts-per-million. A deviation within 0.1% (or roughly 5 ppm at typical peptide masses) is the standard expectation. A larger deviation suggests a sequence error, a modification, or a sample-prep issue — any of which warrant follow-up before the lot is used.

Purity is the percentage of the total chromatographic area attributable to the target peptide, measured by reverse-phase high-performance liquid chromatography (RP-HPLC) — typically with UV detection at 214 nm or 220 nm, which captures the peptide backbone absorbance.

A modern Park Ave specification is ≥99.0% purity by HPLC. The COA should show the chromatogram, the retention time of the main peak, the percent area, and the percent area of all impurity peaks above the reporting threshold (typically 0.1% area). A summary number without the accompanying chromatogram is not sufficient documentation — the practitioner should see the actual trace.

Lyophilized peptides retain residual water. Excessive water content reduces the effective mass of peptide in the vial and can affect long-term stability. The standard test is coulometric Karl Fischer titration, expressed as percent water by mass.

Acceptable water content for a lyophilized peptide is typically ≤8%, with most well-controlled lots in the 2–5% range. The COA should report a numeric value with the method specified.

Peptides synthesized by solid-phase methods carry a counterion to the basic residues — typically acetate after exchange from the trifluoroacetate form used during synthesis. Counterion content is measured by ion chromatography and reported as percent by mass.

A modern Park Ave specification is acetate counterion form, with TFA below the residual reporting limit (typically <1.0%). The clinical significance of TFA at trace levels is debated in the literature, but acetate is the preferred form for most research and clinical contexts.

Bacterial endotoxin (lipopolysaccharide) is measured by Limulus Amebocyte Lysate (LAL) assay, typically the kinetic chromogenic or gel-clot method. The result is expressed in endotoxin units per milligram of peptide (EU/mg).

Acceptable specifications vary by intended research route. A conservative specification for parenteral research use is ≤5 EU/mg; published USP limits for therapeutic injectables can be substantially lower depending on the dose. The COA should report the numeric value and the test method used.

Total aerobic microbial count and total combined yeasts and molds are reported per gram of peptide. For lyophilized peptides, low microbial burden is expected and any growth above the specification is a release-stopping finding.

Sterility per USP <71> is a separate, more rigorous test performed on a representative sample of vials and is not a substitute for bioburden testing on the bulk material. A COA may report one or both depending on the intended use.

These are visual and chemical descriptors. Appearance is typically reported as "white to off-white lyophilized powder." Solubility describes the recommended diluent and the expected behavior on reconstitution. pH is measured on a defined-concentration solution and should be within the documented stability range for the compound.

The COA should attest to the recommended storage condition under which the stability claim was generated — typically −20°C for long-term storage of lyophilized peptide — and the retest or expiry date that applies under those conditions.

A retest date is not a hard expiry; it is the point at which the lot must be re-evaluated against the same specification before continued use. An expiry date is a hard end-of-shelf-life.

A COA missing the HPLC chromatogram is incomplete. A COA without a signed quality officer is not a controlled document. A COA that reports purity to one decimal place without showing the impurity profile hides information. A COA without endotoxin testing is unsuitable for parenteral research applications. In all four cases the right response is to request the full data package rather than accept the summary sheet.

A correctly issued COA is a piece of evidence the practitioner can defend. Anything less should be treated as marketing material.